Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6655) 6655
Publication (888) 888
Book Review (117) 117
Book Chapter (69) 69
Book / eBook (27) 27
Conference Proceeding (10) 10
Newsletter (6) 6
Dissertation (4) 4
Data Set (2) 2
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
animals (4137) 4137
index medicus (2386) 2386
humans (2377) 2377
biochemistry & molecular biology (2251) 2251
cyclic amp - metabolism (1635) 1635
rats (1452) 1452
male (1409) 1409
cell biology (1114) 1114
mice (1030) 1030
signal transduction (950) 950
cyclic gmp - metabolism (875) 875
pharmacology & pharmacy (815) 815
phosphodiesterase (794) 794
camp (782) 782
cyclic amp (775) 775
proteins (766) 766
phosphorylation (757) 757
phosphodiesterase inhibitors - pharmacology (740) 740
female (669) 669
neurosciences (663) 663
cells, cultured (644) 644
kinetics (621) 621
molecular sequence data (548) 548
expression (539) 539
cyclic-amp (501) 501
article (499) 499
3',5'-cyclic-amp phosphodiesterases - metabolism (491) 491
amino acid sequence (486) 486
cyclic amp-dependent protein kinases - metabolism (485) 485
activation (470) 470
physiology (460) 460
dose-response relationship, drug (457) 457
cgmp (454) 454
physiological aspects (451) 451
analysis (446) 446
in vitro techniques (445) 445
research article (443) 443
biophysics (441) 441
dependent protein-kinase (439) 439
phosphoric diester hydrolases - metabolism (438) 438
3',5'-cyclic-amp phosphodiesterases - antagonists & inhibitors (432) 432
cyclic gmp (431) 431
kinases (425) 425
nitric oxide (425) 425
enzymes (423) 423
gene expression (412) 412
cells (406) 406
research (401) 401
chemistry, medicinal (400) 400
calcium - metabolism (396) 396
cell line (390) 390
adenylyl cyclases - metabolism (386) 386
multidisciplinary sciences (385) 385
protein binding (385) 385
cyclic nucleotide phosphodiesterases, type 4 (382) 382
biochemistry (371) 371
cattle (363) 363
structure-activity relationship (360) 360
calcium (340) 340
nitric-oxide (340) 340
inhibition (335) 335
binding sites (332) 332
enzyme inhibitors - pharmacology (330) 330
cyclic-nucleotide phosphodiesterases (322) 322
cyclic adenylic acid (321) 321
microbiology (321) 321
biology (313) 313
life sciences (312) 312
cyclic amp - pharmacology (310) 310
medicine (306) 306
mutation (305) 305
rats, sprague-dawley (295) 295
signal transduction - physiology (293) 293
models, molecular (287) 287
colforsin - pharmacology (283) 283
cyclic gmp - analogs & derivatives (281) 281
signal transduction - drug effects (281) 281
identification (280) 280
rats, wistar (279) 279
enzyme activation (278) 278
cyclic nucleotide phosphodiesterases, type 4 - metabolism (273) 273
rolipram (271) 271
1-methyl-3-isobutylxanthine - pharmacology (270) 270
time factors (270) 270
cyclic-nucleotide phosphodiesterase (266) 266
protein kinases (256) 256
protein kinase a (253) 253
phosphodiesterases (252) 252
science (252) 252
cyclic-gmp (251) 251
gene-expression (249) 249
rodents (246) 246
biochemistry, general (243) 243
binding (238) 238
cyclic amp - physiology (235) 235
protein (235) 235
in-vitro (229) 229
nitric oxide - metabolism (228) 228
protein-kinase (227) 227
chemistry, organic (221) 221
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (17) 17
Chemistry (A D Allen) - Stacks (2) 2
UofT at Mississauga - Stacks (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Collection Dvlpm't (Acquisitions) - Vendor file (1) 1
Gerstein Science - Periodical Stacks (1) 1
Online Resources - Online (1) 1
UTL at Downsview - May be requested (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6696) 6696
German (4) 4
Russian (2) 2
Spanish (2) 2
Chinese (1) 1
French (1) 1
Japanese (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


41. Full Text Multiple Elements Jointly Determine Inhibitor Selectivity of Cyclic Nucleotide Phosphodiesterases 4 and 7
by Huanchen Wang and Yudong Liu and Yuxiang Chen and Howard Robinson and Hengming Ke
Journal of Biological Chemistry, ISSN 0021-9258, 09/2005, Volume 280, Issue 35, pp. 30949 - 30955
Phosphodiesterase (PDE) inhibitors have been widely studied as therapeutics for treatment of human diseases. However, the mechanism by which each PDE family... 
COMPLEX | MESSENGER-RNA | MECHANISM | AMP | CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | CATALYTIC DOMAIN | PDE7A | IDENTIFICATION | CAMP | LYMPHOCYTES | Protein Structure, Tertiary | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Amino Acid Sequence | Cyclic Nucleotide Phosphodiesterases, Type 4 | Humans | Models, Molecular | Molecular Sequence Data | Crystallography, X-Ray | 3',5'-Cyclic-AMP Phosphodiesterases - genetics | Sequence Alignment | 3',5'-Cyclic-AMP Phosphodiesterases - chemistry | 1-Methyl-3-isobutylxanthine - chemistry | Phosphodiesterase Inhibitors - metabolism | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | Molecular Structure | Cyclic Nucleotide Phosphodiesterases, Type 7 | Phosphodiesterase Inhibitors - chemistry | 1-Methyl-3-isobutylxanthine - metabolism | Cyclic AMP - metabolism
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
42. Full Text An improved malachite green assay of phosphate: Mechanism and application
by Feng, Juan and Chen, Yuan and Pu, Jun and Yang, Xiaolan and Zhang, Chun and Zhu, Sha and Zhao, Yunsheng and Yuan, Yonghua and Yuan, Huidong and Liao, Fei
Analytical Biochemistry, ISSN 0003-2697, 2011, Volume 409, Issue 1, pp. 144 - 149
The classical malachite green (MLG) assay of phosphate, which added MLG after molybdate to the acidified reaction solutions of phosphate, tolerated... 
Aggregates | Papaverine | Phosphate | Interference | Malachite green | Cyclic nucleotide phosphodiesterase | CHEMISTRY, ANALYTICAL | PROTEIN | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | COLORIMETRIC ASSAY | BIOCHEMISTRY & MOLECULAR BIOLOGY | BIOCHEMICAL RESEARCH METHODS | INORGANIC-PHOSPHATE | INHIBITION | DRUG DEVELOPMENT | TARGETS | AGENTS | SCATTERING | Amines - chemistry | Molybdenum - chemistry | Rabbits | Rosaniline Dyes - chemistry | Humans | Phosphates - chemistry | Phosphoric Acids - chemistry | Phosphodiesterase Inhibitors - pharmacology | Papaverine - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Recombinant Fusion Proteins - metabolism | Brain - metabolism | Recombinant Fusion Proteins - antagonists & inhibitors | Animals | Spectrophotometry, Ultraviolet - methods | Hydrophobic and Hydrophilic Interactions | Recombinant Fusion Proteins - genetics | Papaverine - chemistry | Phosphodiesterase Inhibitors - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Phosphates | Phosphatases | Isoenzymes | Rain and rainfall
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
43. Full Text Aryl hydrocarbon receptor-interacting protein-like 1 is an obligate chaperone of phosphodiesterase 6 and is assisted by the γ-subunit of its client
by Gopalakrishna, Kota N and Boyd, Kimberly and Yadav, Ravi P and Artemyev, Nikolai O
Journal of Biological Chemistry, ISSN 0021-9258, 07/2016, Volume 291, Issue 31, pp. 16282 - 16291
Phosphodiesterase 6 (PDE6) is the effector enzyme in the phototransduction cascade and is critical for the health of both rod and cone photoreceptors. Its... 
RETINAL DEGENERATION | LEBER CONGENITAL AMAUROSIS | DOMAIN | GENE | BIOCHEMISTRY & MOLECULAR BIOLOGY | MOUSE | ROD CGMP-PHOSPHODIESTERASE | AIPL1 | BETA-SUBUNIT | NONSENSE MUTATION | CYCLIC-GMP PHOSPHODIESTERASE | Retinal Diseases - genetics | Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism | Molecular Chaperones - metabolism | Humans | Molecular Chaperones - genetics | Cercopithecus aethiops | Retinal Diseases - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 6 - genetics | Animals | Adaptor Proteins, Signal Transducing - genetics | HEK293 Cells | Mice | Adaptor Proteins, Signal Transducing - metabolism | COS Cells | phosphodiesterases | protein folding | Signal Transduction | chaperone | phototransduction | photoreceptor
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
44. Full Text Decreased catalytic activity and altered activation properties of PDE6C mutants associated with autosomal recessive achromatopsia
by Grau, Tanja and Artemyev, Nikolai O and Rosenberg, Thomas and Dollfus, Hélène and Haugen, Olav H and Sener, E. Cumhur and Jurklies, Bernhard and Andreasson, Sten and Kernstock, Christoph and Larsen, Michael and Zrenner, Eberhart and Wissinger, Bernd and Kohl, Susanne and Lund University and Oftalmologi, Lund and Ophthalmology, Lund and Lunds universitet
Human Molecular Genetics, ISSN 0964-6906, 02/2011, Volume 20, Issue 4, pp. 719 - 730
Mutations in the gene encoding the catalytic subunit of the cone photoreceptor phosphodiesterase (PDE6C) have been recently reported in patients with autosomal... 
TRANSDUCIN | ROD CGMP PHOSPHODIESTERASE | GENETIC-BASIS | INHIBITORY GAMMA-SUBUNIT | ALPHA-SUBUNIT | BIOCHEMISTRY & MOLECULAR BIOLOGY | GAFA DOMAINS | GENETICS & HEREDITY | MUTATIONS | IDENTIFICATION | BINDING | TOTAL COLOURBLINDNESS | Cyclic Nucleotide Phosphodiesterases, Type 6 - metabolism | Color Vision Defects - enzymology | Humans | Cercopithecus aethiops | Cyclic Nucleotide Phosphodiesterases, Type 6 - antagonists & inhibitors | Substrate Specificity | Cyclic Nucleotide Phosphodiesterases, Type 6 - chemistry | Male | Cyclic Nucleotide Phosphodiesterases, Type 6 - genetics | Color Vision Defects - genetics | Microsatellite Repeats - genetics | Phenotype | RNA Splicing | Animals | Pedigree | Adolescent | Cyclic Nucleotide Phosphodiesterases, Type 5 - genetics | Adult | Female | Mutation | COS Cells | Child | Cyclic Nucleotide Phosphodiesterases, Type 5 - metabolism | Medicinsk genetik | Basic Medicine | Medical Genetics | Medical and Health Sciences | Medicin och hälsovetenskap | Medicinska och farmaceutiska grundvetenskaper
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
45. Full Text Discovery of an Orally Bioavailable, Brain-Penetrating, in Vivo Active Phosphodiesterase 2A Inhibitor Lead Series for the Treatment of Cognitive Disorders
by Mikami, Satoshi and Sasaki, Shigekazu and Asano, Yasutomi and Ujikawa, Osamu and Fukumoto, Shoji and Nakashima, Kosuke and Oki, Hideyuki and Kamiguchi, Naomi and Imada, Haruka and Iwashita, Hiroki and Taniguchi, Takahiko
Journal of Medicinal Chemistry, ISSN 0022-2623, 09/2017, Volume 60, Issue 18, pp. 7658 - 7676
Herein, we describe the discovery of a potent, selective, brain-penetrating, in vivo active phosphodiesterase (PDE) 2A inhibitor lead series. To identify... 
HIPPOCAMPUS | OBSTRUCTIVE PULMONARY-DISEASE | CHEMISTRY, MEDICINAL | PERSPECTIVE | MILRINONE | EFFICACY | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES | CGMP | SYNAPTIC PLASTICITY | ROFLUMILAST | SELECTIVITY | Cyclic Nucleotide Phosphodiesterases, Type 2 - antagonists & inhibitors | Humans | Cognition Disorders - metabolism | Male | Pyrimidines - chemistry | Brain - metabolism | Phosphodiesterase Inhibitors - chemistry | Cognition Disorders - enzymology | Phosphodiesterase Inhibitors - pharmacokinetics | Administration, Oral | Pyrimidines - administration & dosage | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Phosphodiesterase Inhibitors - pharmacology | Rats | Pyrimidines - pharmacology | Cognition Disorders - drug therapy | Drug Discovery | Mice, Inbred ICR | Brain - drug effects | Phosphodiesterase Inhibitors - administration & dosage | Animals | Cyclic GMP - metabolism | Pyrimidines - pharmacokinetics | Mice | Molecular Docking Simulation
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
46. Full Text Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes
by Castro, Liliana R.V and Verde, Ignacio and Cooper, Dermot M.F and Fischmeister, Rodolphe
Circulation, ISSN 0009-7322, 2006, Volume 113, Issue 18, pp. 2221 - 2228
Background - Cyclic guanosine monophosphate (cGMP) is the common second messenger for the cardiovascular effects of nitric oxide (NO) and natriuretic peptides,... 
Sildenafil | Phosphodiesterases | Cyclic GMP | Nitric oxide | Natriuretic peptides | nitric oxide | CARDIAC & CARDIOVASCULAR SYSTEMS | cyclic GMP | CALCIUM CURRENT | DEPENDENT PROTEIN-KINASE | sildenafil | natriuretic peptides | SOLUBLE GUANYLYL CYCLASE | CGMP-SPECIFIC PHOSPHODIESTERASE | CA2+ CURRENT | phosphodiesterases | NITRIC-OXIDE | PERIPHERAL VASCULAR DISEASE | ADENOVIRUS-MEDIATED EXPRESSION | FROG VENTRICULAR MYOCYTES | NUCLEOTIDE-GATED CHANNELS | HEMATOLOGY | HUMAN ATRIAL MYOCYTES | Cyclic GMP - pharmacology | Heart Ventricles - cytology | Rats, Wistar | Cyclic Nucleotide Phosphodiesterases, Type 5 | Cyclic Nucleotide Phosphodiesterases, Type 2 | Humans | Recombinant Fusion Proteins - analysis | Recombinant Fusion Proteins - physiology | Male | Ion Channels - physiology | Natriuretic Peptide, Brain - pharmacology | Phosphoric Diester Hydrolases - physiology | Cell Compartmentation | Sildenafil Citrate | Purines | Biological Transport | Cell Membrane - metabolism | Atrial Natriuretic Factor - pharmacology | Nitric Oxide Donors - pharmacology | Sarcolemma - metabolism | Second Messenger Systems | Sulfones | Isoenzymes - physiology | Adenine - analogs & derivatives | 3',5'-Cyclic-GMP Phosphodiesterases - physiology | Solubility | Phosphodiesterase Inhibitors - pharmacology | Rats | Adenine - pharmacology | Myocytes, Cardiac - chemistry | Piperazines - pharmacology | 1-Methyl-3-isobutylxanthine - pharmacology | Ion Channels - antagonists & inhibitors | Cyclic AMP - pharmacology | Animals | Ion Channels - analysis | Myocytes, Cardiac - drug effects | Cyclic GMP - metabolism | Cyclic Nucleotide-Gated Cation Channels | Myocytes, Cardiac - ultrastructure | Isoenzymes - antagonists & inhibitors | Ion Channel Gating - drug effects | Life Sciences | Cellular Biology | Cell Membrane | cytology | Ion Channels | cGMP | Recombinant Fusion Proteins | Heart Ventricles | Nitric Oxide Donors | Natriuretic Peptide, Brain | Atrial Natriuretic Factor | pharmacology | 3',5'-Cyclic-GMP Phosphodiesterase | chemistry | Sarcolemma | Phosphodiesterase Inhibitors | Myocytes, Cardiac | Piperazines | Isoenzymes | physiology | Adenine | Cyclic AMP | 1-Methyl-3-isobutylxanthine | drug effects | analysis | ultrastructure | antagonists & inhibitors | Phosphoric Diester Hydrolases | analogs & derivatives | metabolism | Ion Channel Gating
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
47. Full Text Phenotypic, chemical and functional characterization of cyclic nucleotide phosphodiesterase 4 (PDE4) as a potential anthelmintic drug target
by Long, Thavy and Rojo-Arreola, Liliana and Shi, Da and El-Sakkary, Nelly and Jarnagin, Kurt and Rock, Fernando and Meewan, Maliwan and Rascón, Alberto A and Lin, Lin and Cunningham, Katherine A and Lemieux, George A and Podust, Larissa and Abagyan, Ruben and Ashrafi, Kaveh and McKerrow, James H and Caffrey, Conor R
PLoS Neglected Tropical Diseases, ISSN 1935-2727, 07/2017, Volume 11, Issue 7, p. e0005680
Background Reliance on just one drug to treat the prevalent tropical disease, schistosomiasis, spurs the search for new drugs and drug targets. Inhibitors of... 
CAENORHABDITIS-ELEGANS | PHARMACOLOGICAL VALIDATION | SCHISTOSOMA-MANSONI | PROTEIN-KINASE | ALZHEIMERS-DISEASE | 5 INHIBITOR ANALOGS | MIRACIDIAL TRANSFORMATION | TRYPANOSOMA-BRUCEI PHOSPHODIESTERASES | CONSERVED REGIONS UCRS | PARASITOLOGY | TROPICAL MEDICINE | CAMP-SPECIFIC PHOSPHODIESTERASES | Schistosoma mansoni - drug effects | Schistosoma mansoni - physiology | Catalytic Domain | Caenorhabditis elegans - genetics | Schistosoma mansoni - anatomy & histology | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Phosphodiesterase 4 Inhibitors - pharmacology | Animals | Caenorhabditis elegans - drug effects | Animals, Genetically Modified - genetics | Anthelmintics - pharmacology | Cloning, Molecular | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Locomotion - drug effects | Caenorhabditis elegans | Schistosomiasis | Care and treatment | Lung diseases, Obstructive | Genetic aspects | Research | Phosphodiesterases | Alzheimer's disease | Asthma | Drugs | Transgenic | Phosphodiesterase IV | Genomes | Parasites | Nucleotides | Drug development | Kinases | Gene sequencing | Parasitic diseases | Tropical environment | Degeneration | Chronic obstructive pulmonary disease | cDNA | Aquatic invertebrates | Catalysis | Phosphodiesterase | 3',5'-Cyclic-nucleotide phosphodiesterase | Lung diseases | Catechol | Gene expression | Diseases | Inhibitors | DNA | Obstructive lung disease | Nematodes | Hypothermia | Lines
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
48. Full Text PDE3, but not PDE4, reduces β1‐ and β2‐adrenoceptor‐mediated inotropic and lusitropic effects in failing ventricle from metoprolol‐treated patients
by Molenaar, Peter and Christ, Torsten and Hussain, Rizwan I and Engel, Andreas and Berk, Emanuel and Gillette, Katherine T and Chen, Lu and Galindo‐Tovar, Alejandro and Krobert, Kurt A and Ravens, Ursula and Levy, Finn Olav and Kaumann, Alberto J
British Journal of Pharmacology, ISSN 0007-1188, 06/2013, Volume 169, Issue 3, pp. 528 - 538
Background and Purpose PDE3 and/or PDE4 control ventricular effects of catecholamines in several species but their relative effects in failing human ventricle... 
inotropism and lusitropism | human heart failure | phosphodiesterases 3 and 4 | noradrenaline and adrenaline | metoprolol | β1 and β2 adrenoceptors | and β | adrenoceptors | Adrenergic beta-1 Receptor Antagonists - adverse effects | Heart Failure - surgery | Cyclic Nucleotide Phosphodiesterases, Type 3 - chemistry | Norepinephrine - pharmacology | Adrenergic alpha-Agonists - chemistry | Phosphodiesterase 3 Inhibitors - pharmacology | Humans | Middle Aged | Adrenergic beta-1 Receptor Antagonists - pharmacology | Heart Failure - physiopathology | Myocardial Contraction - drug effects | Receptors, Adrenergic, beta-1 - chemistry | Adrenergic beta-1 Receptor Antagonists - therapeutic use | Adrenergic beta-Agonists - chemistry | Epinephrine - agonists | Receptors, Adrenergic, beta-2 - chemistry | Cardiotonic Agents - therapeutic use | Cyclic Nucleotide Phosphodiesterases, Type 3 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Adrenergic beta-2 Receptor Antagonists - pharmacology | Adrenergic beta-Agonists - pharmacology | Heart Transplantation | Metoprolol - therapeutic use | Receptors, Adrenergic, beta-1 - metabolism | Drug Resistance - drug effects | Heart Failure - metabolism | Anti-Arrhythmia Agents - therapeutic use | Cardiotonic Agents - pharmacology | Metoprolol - adverse effects | Norepinephrine - agonists | Phosphodiesterase 4 Inhibitors - pharmacology | Receptors, Adrenergic, beta-2 - metabolism | Heart Failure - drug therapy | Heart Ventricles - physiopathology | Anti-Arrhythmia Agents - adverse effects | Adrenergic alpha-Agonists - pharmacology | Heart Ventricles - metabolism | In Vitro Techniques | Epinephrine - pharmacology | Heart Ventricles - drug effects | Research Paper with
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
49. Full Text Isoforms of Cyclic Nucleotide Phosphodiesterase PDE3 and Their Contribution to cAMP Hydrolytic Activity in Subcellular Fractions of Human Myocardium
by Ryan Hambleton and Judith Krall and Eliso Tikishvili and Matthew Honeggar and Faiyaz Ahmad and Vincent C. Manganiello and Matthew A. Movsesian
Journal of Biological Chemistry, ISSN 0021-9258, 11/2005, Volume 280, Issue 47, pp. 39168 - 39174
Three isoforms of PDE3 (cGMP-inhibited) cyclic nucleotide phosphodiesterase regulate cAMP content in different intracellular compartments of cardiac myocytes... 
NATRIURETIC-PEPTIDE | CA2+ CURRENT | RAT CARDIAC MYOCYTES | BIOCHEMISTRY & MOLECULAR BIOLOGY | HEART-FAILURE | NITRIC-OXIDE | DEPENDENT PROTEIN-KINASE | HUMAN VENTRICULAR MYOCARDIUM | SARCOPLASMIC-RETICULUM | GUANYLYL CYCLASE-A | ROLIPRAM INHIBITION | Cyclic GMP - pharmacology | Cyclic Nucleotide Phosphodiesterases, Type 1 | Humans | Cyclic Nucleotide Phosphodiesterases, Type 3 | Isoenzymes - chemistry | Isoenzymes - metabolism | Myocardium - metabolism | Cyclic AMP - metabolism | Calcium Signaling | Recombinant Proteins - metabolism | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Recombinant Proteins - antagonists & inhibitors | Signal Transduction | Isoenzymes - genetics | Enzyme Inhibitors - pharmacology | Recombinant Proteins - chemistry | Recombinant Proteins - genetics | 3',5'-Cyclic-AMP Phosphodiesterases - genetics | Subcellular Fractions - metabolism | Hydrolysis | 3',5'-Cyclic-AMP Phosphodiesterases - chemistry | Cyclic GMP - metabolism | 3',5'-Cyclic-AMP Phosphodiesterases - antagonists & inhibitors | Kinetics | In Vitro Techniques | Isoenzymes - antagonists & inhibitors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
50. Full Text Apremilast is a selective PDE4 inhibitor with regulatory effects on innate immunity
by Schafer, P.H and Parton, A and Capone, L and Cedzik, D and Brady, H and Evans, J.F and Man, H.-W and Muller, G.W and Stirling, D.I and Chopra, R
Cellular Signalling, ISSN 0898-6568, 09/2014, Volume 26, Issue 9, pp. 2016 - 2029
Apremilast, an oral small molecule inhibitor of phosphodiesterase 4 (PDE4), is in development for chronic inflammatory disorders, and has shown efficacy in... 
Phosphodiesterase inhibitor | Apremilast | Spondyloarthropathies | Psoriasis | Preclinical drug evaluation | Psoriatic arthritis | PROTEIN-KINASE-A | CONTROLLED-TRIAL | CAMP-SPECIFIC PHOSPHODIESTERASE | NECROSIS-FACTOR-ALPHA | KAPPA-B | PSORIATIC-ARTHRITIS | CELL BIOLOGY | ORAL PHOSPHODIESTERASE-4 INHIBITOR | CYCLIC-AMP | THALIDOMIDE ANALOGS | B-MEDIATED TRANSCRIPTION | Thalidomide - metabolism | Humans | Male | Thalidomide - pharmacology | Lung Diseases - drug therapy | Thalidomide - analogs & derivatives | T-Lymphocytes - metabolism | T-Lymphocytes - drug effects | Female | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Vomiting - prevention & control | B-Lymphocytes - metabolism | Disease Models, Animal | Cell Line | Cytokines - metabolism | Immunity, Innate - drug effects | Jurkat Cells | Phosphodiesterase 4 Inhibitors - therapeutic use | Mice, Transgenic | Phosphodiesterase 4 Inhibitors - metabolism | Ferrets | Phosphodiesterase 4 Inhibitors - pharmacology | B-Lymphocytes - drug effects | Adaptive Immunity - drug effects | Animals | B-Lymphocytes - immunology | Protein Binding | T-Lymphocytes - immunology | Mice | Thalidomide - therapeutic use | Dendritic cells | Analysis | Development and progression | Genetic engineering | B cells | Biological response modifiers | T cells
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
51. Full Text AMPK antagonizes hepatic glucagon-stimulated cyclic AMP signalling via phosphorylation-induced activation of cyclic nucleotide phosphodiesterase 4B
by Johanns, M and Lai, Y.-C and Hsu, M.-F and Jacobs, R and Vertommen, D and Van Sande, J and Dumont, J.E and Woods, A and Carling, D and Hue, L and Viollet, B and Foretz, M and Rider, M.H
Nature Communications, ISSN 2041-1723, 03/2016, Volume 7, Issue 1, p. 10856
Biguanides such as metformin have previously been shown to antagonize hepatic glucagon-stimulated cyclic AMP (cAMP) signalling independently of AMP-activated... 
GLYCOGEN-METABOLISM | SKELETAL-MUSCLE | CULTURED RAT HEPATOCYTES | HORMONAL-CONTROL | PROTEIN-KINASE | MULTIDISCIPLINARY SCIENCES | MULTISITE PHOSPHORYLATION | BINDING-PROTEIN | GENE-EXPRESSION | MASS-SPECTROMETRY | GLUCOSE-PRODUCTION | AMP-Activated Protein Kinases - metabolism | Phosphorylation | Signal Transduction | Mice, Inbred C57BL | Cells, Cultured | Enzyme Activators - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - genetics | Hepatocytes - metabolism | Amino Acid Motifs | Mice, Knockout | Animals | Glucagon - metabolism | Mice | Enzyme Activation | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Cyclic AMP - metabolism | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | AMP-Activated Protein Kinases - genetics | Hepatocytes - enzymology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
52. Full Text Discovery of potent, selective, bioavailable phosphodiesterase 2 (PDE2) inhibitors active in an osteoarthritis pain model, Part I: Transformation of selective pyrazolodiazepinone phosphodiesterase 4 (PDE4) inhibitors into selective PDE2 inhibitors
by Plummer, Mark S and Cornicelli, Joseph and Roark, Howard and Skalitzky, Donald J and Stankovic, Charles J and Bove, Susan and Pandit, Jayvardhan and Goodman, Annise and Hicks, James and Shahripour, Aurash and Beidler, David and Lu, Xiao Kang and Sanchez, Brian and Whitehead, Christopher and Sarver, Ron and Braden, Timothy and Gowan, Richard and Shen, Xi Qiang and Welch, Katherine and Ogden, Adam and Sadagopan, Nalini and Baum, Heidi and Miller, Howard and Banotai, Craig and Spessard, Cindy and Lightle, Sandra
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 06/2013, Volume 23, Issue 11, pp. 3438 - 3442
We identified potent, selective PDE2 inhibitors by optimizing residual PDE2 activity in a series of PDE4 inhibitors, while simultaneously minimizing PDE4... 
Phosphodiesterase 2 (PDE2)inhibition | Structure-based drug design | Osteoarthritis(OA)pain | ISOZYME | Osteoarthritis(OA) pain | CHEMISTRY, MEDICINAL | CGMP | CHEMISTRY, ORGANIC | Phosphodiesterase 2 (PDE2) inhibition | Cyclic Nucleotide Phosphodiesterases, Type 2 - antagonists & inhibitors | Phosphodiesterase Inhibitors - therapeutic use | Catalytic Domain | Phosphodiesterase 4 Inhibitors - chemistry | Dihydropyridines - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 2 - metabolism | Crystallography, X-Ray | Structure-Activity Relationship | Dihydropyridines - metabolism | Osteoarthritis - drug therapy | Dihydropyridines - therapeutic use | Azirines - chemistry | Animals | Phosphodiesterase Inhibitors - metabolism | Azirines - therapeutic use | Azirines - metabolism | Protein Binding | Phosphodiesterase Inhibitors - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 4 - metabolism | Drug Evaluation, Preclinical | Binding Sites | Cyclic Nucleotide Phosphodiesterases, Type 4 - chemistry | Disease Models, Animal | Osteoarthritis
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
53. Full Text PDE4 cAMP phosphodiesterases: Modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization
by Houslay, Miles D and Adams, David R
Biochemical Journal, ISSN 0264-6021, 02/2003, Volume 370, Issue 1, pp. 1 - 18
cAMP is a second messenger that controls many key cellular functions. The only way to inactivate cAMP is to degrade it through the action of cAMP... 
Chronic obstructive pulmonary disease (COPD) | Phosphorylation | Arrestin | Rolipram | Targeting | Asthma | DROSOPHILA-MELANOGASTER | BIOCHEMISTRY & MOLECULAR BIOLOGY | LIVER PLASMA-MEMBRANES | rolipram | DEPENDENT PROTEIN-KINASE | asthma | AMP-SPECIFIC PHOSPHODIESTERASE | arrestin | targeting | chronic obstructive pulmonary disease (COPD) | N-TERMINAL DOMAIN | A-MEDIATED PHOSPHORYLATION | PHOSPHATIDIC-ACID | MOLECULAR-CLONING | CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE | phosphorylation | SMOOTH-MUSCLE CELLS | Cell Compartmentation | 3',5'-Cyclic-AMP Phosphodiesterases - metabolism | Catalytic Domain | 3',5'-Cyclic-AMP Phosphodiesterases - chemistry | Cyclic Nucleotide Phosphodiesterases, Type 4 | Signal Transduction | Humans | Models, Molecular | Protein Conformation | Pulmonary Disease, Chronic Obstructive - enzymology
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights